CVRx Barostim BENEFIT-HF rationale: expanding baroreflex activation therapy from LVEF ≤35% to ≤50% heart failure
Summary
CVRx published the scientific rationale for BENEFIT-HF — the 2,500-patient randomized controlled trial expanding Barostim baroreflex activation therapy from the current heart failure indication (LVEF ≤35%) to an expanded population including patients with LVEF up to 50% (heart failure with mid-range ejection fraction, HFmrEF) and NT-proBNP up to 5,000 pg/mL. The rationale builds on the BeAT-HF 7-year RCT demonstrating all-cause mortality benefit and quality of life improvement with Barostim in the current indication, and on the shared pathophysiology of sympathetic nervous system activation across all heart failure subtypes regardless of ejection fraction.
Why it matters
BENEFIT-HF targeting LVEF up to 50% addresses the fastest-growing and most treatment-neglected heart failure population — HFmrEF and HFpEF affect more than half of all heart failure patients globally and have received FDA-approved pharmacotherapy only in the past 3-5 years (SGLT2 inhibitors). The neurological mechanism of Barostim — restoring autonomic balance by activating baroreceptors — applies equally across ejection fraction subtypes, making the expansion scientifically rational and the 3x patient population expansion commercially transformative.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial